Humoral response to anti-COVID immunization and SARS-CoV-2 infection in HIV-infected persons

Background/Aim. At the beginning of the coronavirus disease 2019 (COVID-19) pandemic, human immunodeficiency virus (HIV)-infected persons (HIP) were considered to be at an increased risk of more severe forms of the disease. Although vaccination of HIP is deemed essential, data on the humoral response to both infection and vaccination in this population are inconsistent, particularly when comparing different vaccine types. The aim of this study was to examine factors that could influence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike protein antibody titers in HIP after vaccination and/or exposure to the virus. Methods. The study included all HIP who came for routine check-ups to the Center for HIV/AIDS of the University Clinical Center of Vojvodina, Serbia, from April to December 2022 and who had received at least two doses of the vaccine or had a positive history of COVID-19. Data on age, duration of antiretroviral therapy (ART), nadir and current CD4+ and CD8+ T-cell counts, and type of vaccine were collected from medical records and the national data-base. Immunoglobulin G (IgG) antibodies against SARS-CoV-2 spike protein were determined in the sera of HIP using the AdviseDx SARS-CoV-2 IgG II assay. Results. The research included 226 HIP with undetectable viremia, in 96.3% of cases, the CD4 T-lymphocyte count was over 350 cells/mm3. Out of 171 HIP who received at least two doses of a vaccine, 64 (37.4%) were both vaccinated and had COVID-19 and 107 (62.6%) were vaccinated and had no evidence of COVID-19. Among the vaccinated participants, 62% received three doses and 38% received two vaccine doses. Regarding the type of vaccine, 59.6% of participants received a messenger ribonucleic acid (mRNA) vaccine, 25.1% an inactivated vaccine, and 15.3% received a vector vaccine. A better humoral response was observed in the mRNA compared to the inactivated vaccines and in three compared to two doses in the case of mRNA vaccines. Age and duration of ART negatively correlated with antibody titers, while the number of CD8 T-cells had a positive correlation. Conclusion. The study showed the immunogenicity and safety of full vaccination against COVID-19 in HIP with any of the available vaccines.

Authors

Institutions

Publication Details

Journal
Vojnosanitetski pregled
Published
2025-01-01
DOI
https://doi.org/10.2298/vsp241206022m
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Humoral response to anti-COVID immunization and SARS-CoV-2 infection in HIV-infected persons

Romana Mijović, Vanja Andrić, Aleksandra Bulovic, Snežana Brkić et al.
Vojnosanitetski pregled
SARS-CoV-2 and COVID-19 Research
article

Humoral response to anti-COVID immunization and SARS-CoV-2 infection in HIV-infected persons

Romana Mijović, Vanja Andrić, Aleksandra Bulovic, Snežana Brkić, D. Zuvic, Daniela Marić
article en

Abstract

Background/Aim. At the beginning of the coronavirus disease 2019 (COVID-19) pandemic, human immunodeficiency virus (HIV)-infected persons (HIP) were considered to be at an increased risk of more severe forms of the disease. Although vaccination of HIP is deemed essential, data on the humoral response to both infection and vaccination in this population are inconsistent, particularly when comparing different vaccine types. The aim of this study was to examine factors that could influence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike protein antibody titers in HIP after vaccination and/or exposure to the virus. Methods. The study included all HIP who came for routine check-ups to the Center for HIV/AIDS of the University Clinical Center of Vojvodina, Serbia, from April to December 2022 and who had received at least two doses of the vaccine or had a positive history of COVID-19. Data on age, duration of antiretroviral therapy (ART), nadir and current CD4+ and CD8+ T-cell counts, and type of vaccine were collected from medical records and the national data-base. Immunoglobulin G (IgG) antibodies against SARS-CoV-2 spike protein were determined in the sera of HIP using the AdviseDx SARS-CoV-2 IgG II assay. Results. The research included 226 HIP with undetectable viremia, in 96.3% of cases, the CD4 T-lymphocyte count was over 350 cells/mm3. Out of 171 HIP who received at least two doses of a vaccine, 64 (37.4%) were both vaccinated and had COVID-19 and 107 (62.6%) were vaccinated and had no evidence of COVID-19. Among the vaccinated participants, 62% received three doses and 38% received two vaccine doses. Regarding the type of vaccine, 59.6% of participants received a messenger ribonucleic acid (mRNA) vaccine, 25.1% an inactivated vaccine, and 15.3% received a vector vaccine. A better humoral response was observed in the mRNA compared to the inactivated vaccines and in three compared to two doses in the case of mRNA vaccines. Age and duration of ART negatively correlated with antibody titers, while the number of CD8 T-cells had a positive correlation. Conclusion. The study showed the immunogenicity and safety of full vaccination against COVID-19 in HIP with any of the available vaccines.

Vojnosanitetski pregledVol. 82(4)
University of Novi Sad (RS), Klinički centar Vojvodine (RS)
Openalex Percentile: Top 89%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.